Guild Investment Management Inc increased Main Street Capital Corp (MAIN) stake by 43.7% reported in 2018Q3 SEC filing. Guild Investment Management Inc acquired 12,718 shares as Main Street Capital Corp (MAIN)’s stock declined 6.09%. The Guild Investment Management Inc holds 41,822 shares with $1.61M value, up from 29,104 last quarter. Main Street Capital Corp now has $2.26 billion valuation. The stock increased 0.05% or $0.02 during the last trading session, reaching $37. About 195,158 shares traded. Main Street Capital Corporation (NYSE:MAIN) has declined 5.66% since February 10, 2018 and is downtrending. It has underperformed by 5.66% the S&P500. Some Historical MAIN News: 03/05/2018 – MAIN STREET CAPITAL CORP – NET ASSET VALUE OF $23.67 PER SHARE AT MARCH 31, 2018; 06/03/2018 Main Street Announces New Portfolio Investment; 15/03/2018 – Hometown Source: Beer-serving bookstore could open on Mainstreet in time for summer; 30/05/2018 – Mainstreet Announces Normal Course Issuer Bid; 06/03/2018 – MAIN STREET CAPITAL – CO ALONG WITH CO-INVESTOR, PARTNERED WITH NEXREV TO FACILITATE TRANSACTION; 03/04/2018 – S&P REVISES MAIN STREET CAPITAL CORP. OUTLOOK TO ‘NEGATIVE’ FROM ‘STABLE’; RATING ‘BBB’; 05/04/2018 – MAIN STREET REPORTS NEW PORTFOLIO INVESTMENT $35.2M; 06/03/2018 – MAIN STREET CAPITAL – CO, CO-INVESTOR PROVIDING NEXREV UNDRAWN CREDIT FACILITY TO SUPPORT ITS GROWTH INITIATIVES, WORKING CAPITAL; 13/04/2018 – Balfour Beatty Communities Selected to Manage Mainstreet at Conyers; 03/05/2018 – MAIN STREET 1Q INVESTMENT EPS 63C, EST. 59C
Xbiotech Inc (NASDAQ:XBIT) had a decrease of 5.26% in short interest. XBIT’s SI was 1.65M shares in February as released by FINRA. Its down 5.26% from 1.74M shares previously. With 23,200 avg volume, 71 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 8.38%. The stock decreased 6.62% or $0.6 during the last trading session, reaching $8.46. About 466,914 shares traded or 251.58% up from the average. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 10, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” on January 23, 2019, also Nasdaq.com with their article: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” published on January 28, 2019, Benzinga.com published: “50 Biggest Movers From Yesterday – Benzinga” on February 06, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Benzinga.com and their article: “62 Biggest Movers From Yesterday – Benzinga” published on February 07, 2019 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut – Benzinga” with publication date: February 07, 2019.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $303.04 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
More notable recent Main Street Capital Corporation (NYSE:MAIN) news were published by: Seekingalpha.com which released: “Main Street makes a new investment, exits another – Seeking Alpha” on February 06, 2019, also Globenewswire.com with their article: “New Research: Key Drivers of Growth for Main Street Capital, Northrop Grumman, Verisk Analytics, Celanese, FormFactor, and Kopin â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” published on January 16, 2019, Investorplace.com published: “GOOG vs. GOOGL: Everything You Need to Know About the Google Stock Split – Investorplace.com” on February 10, 2019. More interesting news about Main Street Capital Corporation (NYSE:MAIN) were released by: Seekingalpha.com and their article: “Deutsche Bank Needs A New Strategy – Seeking Alpha” published on February 05, 2019 as well as Seekingalpha.com‘s news article titled: “Main Street’s 6.8% Yield: Despite Intensifying Risks, It’s Worth Considering – Seeking Alpha” with publication date: December 28, 2018.